Showing results (271-280 of 364) with videos related to
Sort By:
Pageof 37
American Journal of Public Health|February 3, 2007
Promoting sun safety among US Postal Service letter carriers: impact of a 2-year interventionJoni A Mayer, Donald J Slymen, Elizabeth J Clapp, et al.The Journal of Investigative Dermatology|March 22, 2003
Genetic heterogeneity in erythrokeratodermia variabilis: novel mutations in the connexin gene GJB4 (Cx30.3) and genotype-phenotype correlationsGabriele Richard, Nkecha Brown, Fatima Rouan, et al.Dermatology and Therapy|February 12, 2026
Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 StudiesAndrew Blauvelt, Leon Kircik, Eric L Simpson, et al.Current Medical Research and Opinion|December 3, 2024
Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD RegistryMichael A Haft, Keith D Knapp, Ami Claxton, et al.The Journal of Allergy and Clinical Immunology. in Practice|February 3, 2023
Racial and Ethnic Disparities in Allergen Immunotherapy Prescription for Allergic RhinitisSunjay Modi, Matthew R Norris, Victoria Nguyen, et al.Journal of the American Academy of Dermatology|October 7, 2008
Cutaneous T-cell lymphoma and Staphylococcus aureus colonizationVictoria Nguyen, Richard H Huggins, Terakeith Lertsburapa, et al.Journal of Drugs in Dermatology : JDD|June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.Dermatitis : Contact, Atopic, Occupational, Drug|February 19, 2025
Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD RegistryDawn Z Eichenfield, Keith D Knapp, Ami Claxton, et al.Dermatology and Therapy|June 15, 2023
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 StudyAmy S Paller, Carsten Flohr, Lawrence F Eichenfield, et al.Pageof 37